arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ZEVRA THERAPEUTICS, INC.

ZVRA
$11.87 ▲ +1.33 (+12.62%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bullish
auto_awesome

Analytical Summary

ZEVRA THERAPEUTICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $656.5M
Dividend Yield
Revenue Growth 350.9%
Op. Margin -59.1%
ROIC -27.9%
FCF / Share $-0.04
Trailing P/E 8.5x
Price / Book 4.4x
FCF Yield
Debt / Equity 0.40
info Valuation on last close. End-of-day price, Aug 6, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$106.47M
↑ +350.9%
Net Income Profit after all expenses
$83.23M
↑ +178.9%
Operating Margin Operating profit as % of sales
-59.1%
↑ +84.0% 4th
FCF / Share Free cash flow per share
$-0.04
↑ +97.1%
Long-Term Debt Long-term obligations
$61.93M
↑ +4.1%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
41
Returns
97
Financial Health
43
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 51 quarters